Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
A phase 2 trial of TYRA-300 in bladder & urothelial cancer, run by Tyra Biosciences, Inc, now recruiting.
Overview
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer is a phase 2 interventional study registered as NCT06995677 by Tyra Biosciences, Inc, with 90 participants planned, started 2025-06-27 and due to reach its primary completion in 2028-02. Interventions recorded: TYRA-300 60mg, TYRA-300 50mg and TYRA-300 Dose TBD.
Similar pages
not linked directly; found by shared links- TrialSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Shares TYRA-300, Tyra Biosciences, Bladder & urothelial cancer and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialSafety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Bladder & urothelial cancer and the tag pipeline.